Mylan tops profit estimates as newer drugs spur North America growth
Mylan NV beat Wall Street estimates for third-quarter profit on Tuesday, as its biggest market, North America, benefited from launches of lung disease therapies Wixela and Yupelri.
Mylan NV beat Wall Street estimates for third-quarter profit on Tuesday, as its biggest market, North America, benefited from launches of lung disease therapies Wixela and Yupelri.